The domestic market will continue to move up as long as international markets remain stable. The recent liquidity rush will continue into emerging markets, says Ajay Srivastava, CEO of Dimensions Consulting. Investors are now hoping for an economic recovery. If results are not visible in the next one or two quarters, skepticism will return, he says, adding that a 5-10 percent increase on earnings per share (EPS) side is legitimate. “The current rally is simmering to a point where non-performing stocks are not getting penalised,” he says. It is time for investors to look at stocks that are performing well. It is advisable to now move from smallcaps to higher midcaps with valuations of Rs 200 crore and above, he says. Srivastava is bullish on oil marketing companies and the cement sector over a three year perspective. The cycle for pharmaceutical space is also changing and investors can start investing again. The value lag is the most in public sector banks, but they can give good returns in near-term, Srivastava says. The Good & Services Tax (GST) Bill is not relevant for the market now. If it passes in this session, some bump-up will be seen, but even if doesn’t impact it will not be great, he says.
Tuesday, 26 July 2016
Home »
» It's time to look at well-performing stocks-:- Equity Research
It's time to look at well-performing stocks-:- Equity Research
04:27
Related Posts:
Infosys says seeing client-specific softness after Brexit-:- Equity Research IT services provider Infosys is seeing some 'softness' in clients after Britain voted in June to leave the European Union, a top company executive said during an analyst meet on Friday. Infosys will be in a better posit… Read More
MFs asset base from B15 cities up 19% to Rs 2 lakh cr-:- Equity Research Contribution of small towns -- known as beyond the top 15 cities (B15) -- to mutual funds' asset base in India has surged 19 percent to Rs 2.02 lakh crore in last fiscal. Mutual funds' assets under management (AUM) from B… Read More
Trastuzumab marketing approval may come in 12-18 months-:- Equity Research The European Medicines Agency (EMA) has accepted to review Mylan and Biocon ’s application for a biosimilar called Trastuzumab, used for certain breast and gastric cancers. Terming it as ‘milestone’ for the company, Bioco… Read More
NPCI's Unified Payments Interface goes live-:- Equity Research National Payments Corporation of India (NPCI) today said the Unified Payments Interface (UPI) is live and currently available for customers of 21 banks. UPI is a payment solution which empowers a recipient to initiate the… Read More
Specified borrower norms to hit banks with high current A/c-:- Equity Research The Reserve Bank of India’s new norms for "specified borrowers" are likely to impact banks with higher current accounts, according to State Bank of India. SBI’s CASA stems more from savings accounts and not current accoun… Read More
0 comments:
Post a Comment